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Abstract 
This paper explores the question: Can interventions focusing on healing the gut microbiome of a 
prediabetic patient prevent or delay the onset of type 2 diabetes? Diabetes is a major health 
problem that is becoming the biggest epidemic of the 21st century. Efforts to derail the 
progression of disrupted blood glucose metabolism are often futile leaving patients frustrated 
with a lifelong burden of disease management. Recent studies suggest that collectively the gut 
microbiome acts as an endocrine organ and that injury to this “organ” can lead to dysfunctional 
glucose regulation. A comprehensive literature review revealed that further studies are needed to 
explore alternative approaches to restoring normal glucose regulation. This proposed 
quantitative, experimental study aims to explore the effectiveness of a weekly program focusing 
on the establishment of a healthy gut microbiome to prevent the development of diabetes. The 
proposed sample will be 100 prediabetic adult patients (ages 25-65) who will be randomly 
divided into two groups: a treatment (Group A) and a control (Group B). All participants will 
provide a baseline fasting blood glucose, A1C and a fecal sample before the start of the study. 
Group A will attend an intensive educational program that consists of hour-long weekly 
meetings for 12 weeks.  Group A will attend weekly discussions of evidence-based research on 
ways to promote a healthy gut microbiome. Activities that harm the gut thus promoting the 
growth of pathogenic bacteria will also be discussed and discouraged. Group B, the control 
group, will receive usual care which may or may not include recommendations from a physician 
about exercise, diet and weight loss. At the end of the study, we will compare the two groups’ 
fasting blood glucose, A1C, and fecal microbiome composition. 
         Keywords: gut microbiota, gut microbiome, prediabetes, diabetes, glucose metabolism 
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Gut Microbiota and the Development of Type 2 Diabetes 
The Centers for Disease Control estimated in 2018 that 34.5% of the adult U.S. 
population has prediabetes and 10.5% of the U.S. population has diabetes (2019). The CDC 
cited a study by Gregg et al. in 2014 warning that two out of every five Americans are 
expected to develop type 2 diabetes in their lifetime. A primary nursing role is to decrease the 
prevalence of a disease such as type 2 diabetes by identifying the underlying cause and 
addressing it.  In an attempt to identify the underlying cause of chronic diseases ranging from 
metabolic disease to gastrointestinal disorders to colorectal cancer, Hills et al. discuss how 
recent research findings implicate the gut microbiome as the major influencer in the 
development of these disorders (2019).  
Humans have co-evolved with trillions of microbes, predominantly bacteria, living 
symbiotically on and within various sites of the human body. New discoveries are being made 
regarding the vital role the human microbiome plays in health and in disease. Microbiota is 
defined as the microorganisms, including bacteria, fungi, and viruses, present in a defined 
environment, such as a person’s oral cavity, genital organs, respiratory tract, skin, and 
gastrointestinal system (Lloyd-Price et al., 2016). There are localized differences in the 
microbiota of each person and microbiota from the skin will be radically different from gut 
microbiota. It is estimated that there are roughly equal numbers of microbial cells inhabiting 
the human body as there are human cells (Sender et al., 2016). The human microbiome is 
defined as the collection of genomes, or DNA, from all the microorganisms in the 
environment (Kho et al., 2018). Of all the human microbiomes, the gut microbiome houses the 
most populous and diverse microbial communities. The gut microbiome, a topic of rapidly 
growing research, has been referred to as a separate “organ” or the “second human genome” 
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due to its large involvement in metabolic and immune activity (Ferranti et al., 2014). 
Advances in technology, such as next-generation DNA sequencing (e.g., 16s rRNA 
sequencing), have led to a surge in microbiome research as analysis has become faster and less 
costly, thus more available. These advances have allowed researchers to identify the 
microbiota present in the gut via stool sampling and to identify what physiological roles the 
microbiota plays. While a diverse microbiota is considered healthier, the ideal composition for 
a “healthy gut microbiota” has not yet been identified. However, a distinct microbial profile is 
becoming apparent for individuals with metabolic disorders and glucose dysfunction. For 
example, some researchers suggest that people with type 2 diabetes have a decreased number 
of bacteria that produce short-chain fatty acids (e.g., acetate, propionate, and butyrate) (Lv et 
al., 2018). Short-chain fatty acids are involved in mechanisms related to gut barrier function, 
glucose homeostasis, immunomodulation, appetite regulation, and obesity (Chambers et al., 
2018). In summary, a closer look at the complex role of the gut microbiota is needed to 
understand the development of glucose intolerance and to prevent the onset of type 2 diabetes. 
Literature Review 
The objective for this literature review is to explore various studies and see if their 
findings can answer the following questions: What is the relationship between gut microbiota 
and glucose metabolism; and can certain practices either harm gut microbiota populations or 
promote a healthy gut microbiota to prevent the development of diabetes? 
Search Strategy 
The research literature was explored using multiple databases of the Dominican 
University of California library, such as UpToDate and CINAHL, as well as Google Scholar. 
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Various combinations of keywords were utilized in the search for research articles including the 
following: gut microbiota, gut microbiome, prediabetes, prediabetic, type 2 diabetes, glucose 
regulation, dysbiosis, artificial sweeteners, antibiotics, exercise, and fiber intake. 
Six research articles were retrieved to create the literature review of this paper. These 
articles explore how various activities influence the health of our gut microbiota for better or for 
worse; either protecting us from developing diabetes or predisposing us to glucose metabolism 
dysfunction. 
Although there is extensive research on the gut microbiome and how it affects different 
systems of our body, it was rather difficult finding primary quantitative research conducted on a 
large sample of human subjects related specifically to diabetes and the gut microbiota. The 
majority of research has been conducted on mice and the gut microbiota with a focus on 
inflammatory bowel diseases. Analysis of the gut microbiome can be expensive and tricky to 
manipulate due to its location and anaerobic microbiota. In fact, only in the last decade, as a 
result of the widespread use of polymerase chain reaction and DNA sequencing, 16S rDNA 
sequencing has allowed greater exploration of the role of the gut microbiome “including accurate 
identification of bacterial isolates and the discovery of novel bacteria” (Woo et al., 2008).  Many 
studies included in this review utilized human fecal samples to explore the complex way that the 
gut microbiota interacts with the body’s systems.  
Road Map 
The six articles discussed in this literature review are divided into three categories. The 
first section is called “The Connection Between Gut Microbiome Compositions and Glucose 
Metabolism.” It contains two articles that compare the gut microbiome composition of 
individuals with normal blood glucose regulation with that of individuals with prediabetes or 
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diabetes type 2. The comparison shows that a diverse gut microbiota is positively correlated with 
normal glucose regulation. The second section is called “Activities that Result in Dysbiosis,” and 
includes two research articles that explore practices that harm the gut microbiota, namely 
antibiotic use and nonnutritive sweetener consumption. These activities ultimately increase the 
risk of developing diabetes. The last section of the literature review is called “Activities that 
Promote Good Gut Health” and it discusses two articles that focus on exercise and fiber intake 
and their positive effects on gut microbiota. The objectives, methods, and findings of each article 
are discussed in detail, along with the study’s strengths or limitations when appropriate. In 
addition, each article prompts a brief discussion of relative nursing implications making the 
research findings in these articles immensely valuable and practical. See Appendix A for a 
summary of the literature review. 
 The Connection Between Gut Microbiome Compositions and Glucose Metabolism 
         The article Aberrant Intestinal Microbiota in Individuals with Prediabetes by Allin et al. 
(2018) compared the gut microbiota of adults with prediabetes, obesity, insulin resistance, 
dyslipidemia, and low-grade inflammation with individuals with normal blood glucose 
regulation. The purpose of this study was to see if specific gut microbiota profiles are associated 
with prediabetes and a range of clinical biomarkers of poor metabolic health (Allin e al., 2018). 
Their inquiry was prompted by a former study called Disentangling Type 2 Diabetes and 
Metformin Treatment Signatures in the Human Gut Microbiota by Forslund et al. (2017). In the 
former study, associations between gut microbiota and type 2 diabetes were found, however, the 
accuracy of those associations were called into question by Allin et al. because individuals with 
diabetes 2 were taking metformin which actually alters gut microbiota. Therefore, Allin et al.’s 
newer study includes individuals not currently treated with glucose-lowering drugs. 
GUT MICROBIOTA AND THE DEVELOPMENT OF TYPE 2 DIABETES  9 
This study compared the gut microbiota of 134 treatment-naïve Danish adults with 
prediabetes (n=268) with 134 Danish age- and sex-matched adults with normal blood glucose. 
Prediabetes is defined as a fasting plasma glucose of 6.1-7.0 mmol/l or HbA1c of 6.0-6.5%. The 
design of this study is quantitative involving the analysis of fasting blood samples and the 
measurement of plasma high-sensitivity C-reactive, HbA1c, plasma glucose, triacylglycerol, and 
insulin levels. Fecal samples were collected by the participants at home and then they were 
frozen. The fecal microbiota composition was later profiled by 16S rRNA sequencing. This 
sequencing analysis “is a standard method in bacterial taxonomy and identification and is based 
on the detection of sequence differences (polymorphisms) in the hypervariable regions of the 
16S rRNA gene which is present in all bacteria” (Kim et al., 2011). 
The results of the analyses were that individuals with prediabetes had a depletion of 
several butyrate-producing bacteria compared to the individuals who had normal blood glucose 
metabolism. Specifically, Allin et al. found a decreased abundance of the genus Clostridium and 
the mucin-degrading bacterium A. muciniphila (2018). Butyrate is one of the three main short-
chain fatty acids produced by the “friendly” bacteria in your gut. Multiple studies have found 
that butyrate has anti-inflammatory and anti-cancer properties; it can improve glucose 
metabolism and insulin sensitivity; and it can improve symptoms of ulcerative colitis and 
Crohn's disease (McNabney & Henagan, 2017). 
There are important nursing implications of the findings that increased species diversity 
of the gut microbiota is associated with improved glucose regulation. These findings should 
guide discussions on the prevention and treatment of prediabetes. Reversing the depletion as well 
as preserving the populations of butyrate-producing bacteria in our gut could possibly delay the 
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onset of glucose metabolism dysfunction and other related chronic conditions, including 
metabolic syndrome. 
The article Human Gut Microbiota Changes Reveal the Progression of Glucose 
Intolerance by Zhang et al. (2013) examined the relationship of gut microbiota with the 
development of type 2 diabetes. This quantitative, comparative study included 121 Chinese Han 
subjects that were divided into three distinct groups of varying glucose tolerance: Normal 
glucose tolerance (n=44), prediabetes (n=44), and newly diagnosed type 2 diabetes (n=13). Gut 
microbiota were analyzed using 16S rDNA-based sequencing. Disruptions in the normal balance 
of gut microbial populations were observed in the type 2 diabetes group. Metabolic parameters 
(insulin measurements, A1c, lipid profiles, BP, CRP, WHR, etc.) and microbiota diversity were 
compared and there was a significant association between the two. There was a higher 
abundance of butyrate-producing bacteria (e.g. Akkermansia muciniphila, and Faecalibacterium 
prausnitzii) in the normal glucose tolerance group than in the pre-diabetes group (Zhang et al., 
2013). In the type 2 diabetic group, the abundance of Bacteroides at the genus level was half that 
of the normal glucose tolerance group and pre-diabetic group (Zhang et al., 2013). The study also 
found that Verrucomicrobia had a significantly lower abundance in both the pre-diabetic and 
type 2 diabetic groups (Zhang et al., 2013). Previous studies show that Verrucomicrobia may be 
a potential marker of type 2 diabetes (Barlow et al., 2015). 
The nursing implication for this research is that gut microbiota is altered in different 
glucose intolerance status’ and therefore plays a role in the pathogenesis of diabetes. Further 
studies are needed to explore this relationship so that we can prevent and treat glucose metabolic 
dysfunction. 
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Activities That Result in Dysbiosis 
The article Gut Microbial Diversity in Antibiotic-Naïve Children After Systemic 
Antibiotic Exposure: A Randomized Controlled Trial by Doan et al. (2017) evaluated the effects 
of azithromycin on the gut microbiome diversity of children from an antibiotic-naïve community 
in Niger. This article was found on Iceberg using the keywords: microbial diversity and 
antibiotics. In this study, a population-based sample of 80 children (n=80), 1-60 months old, 
from Niger, was randomized to receive a single dose or oral azithromycin or placebo (Doan et 
al., 2017). The median age was 3 years old. After 5 days of treatment, 40 children were analyzed 
from the antibiotic group and 40 from the placebo group. The goal of this study was to compare 
the two groups’ fecal samples that were collected immediately before the administration of the 
antibiotic and again 5 days after treatment. The samples were then profiled using 16S rRNA 
sequencing to identify bacteria thus determine the samples’ composition and diversity. The 
design of this study was quantitative. The authors utilized a population-based sample randomized 
to receive the independent or the dependent variable. The results were statistically analyzed. 
The outcome of the trial showed that “oral administration of azithromycin definitively 
decreases the diversity of the gut microbiome of children in an antibiotic-naive community” 
(Doan et al., 2017). The limitations of this study are the use of a pediatric population as the 
sample and the rural location in Niger. The results may not be generalizable to all ages or 
locations in the world. Furthermore, the second sample was collected after only 5 days showing 
that the antibiotic caused a short-term decrease in diversity but not necessarily a long-term 
change. A longitudinal study with a randomized control group of various ages and from various 
cities in the United States over a longer period of time would prove useful for this topic. 
Nevertheless, this study showed that even a single dose of antibiotics results in a reduction of 
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bacterial diversity. Antibiotic use may disrupt normal glucose regulation. The number of people 
diagnosed with diabetes continues to rise in the US. Therefore, healthcare providers need to 
thoroughly analyze the risks and benefits associated with antibiotic use before carelessly 
prescribing them to patients. 
The article Are Nonnutritive Sweeteners Obesogenic? Associations Between Diet, Faecal 
Microbiota, and Short-Chain Fatty Acids in Morbidly Obese by Farup et al. (2019) explored 
changes in fecal microbiota and short-chain fatty acids of obese adults with a diet containing 
nonnutritive sweeteners. NNSs are also known as artificial sweeteners.  
This study included 14 men and 75 women from Norway with morbid obesity (defined as 
BMI >40 or >35 kg/m2 with obesity-related comorbidity) and with an average BMI of 41.8 
(Farup et al., 2019). The ages of the participants ranged from 18-65 with a mean age of 44.6. All 
participants gave their medical history, had a physical exam, and had blood and fecal samples 
collected. Their diet was assessed with a validated food frequency questionnaire. Participants had 
an average intake of NNSs 7.5 units/day (SD 3.2; range 0–43). One unit of NNSs was equivalent 
to 100 mL beverage with NNSs or 2 tablets/teaspoons of NNSs (Farup et al., 2019).  The fecal 
microbiota was assessed with a GA-map dysbiosis test. This advanced DNA testing targets 
variable regions (V3 to V7) of the bacterial 16S rRNA gene in order to identify bacteria present 
at different taxonomic levels (Farup et al., 2019). The short-chain fatty acids were assessed using 
gas chromatography and flame ionization detection (Farup et al., 2019). This is a quantitative, 
cross-sectional study of subjects who had been referred for evaluation for bariatric surgery in a 
hospital in Norway. 
The findings of this study were that fecal butyric acid was positively associated with the 
intake of starch and negatively associated with the intake of nonnutritive sweeteners (partial 
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correlation=0.264 and partial correlation=-0.274 respectively) (Farup et al., 2019). NNSs were 
associated with changes in four out of 39 bacterial groups. Tests revealed reduced amounts of 
Faecalibacterium prausnitzii, a butyrate-producing bacteria and reduced amounts of Bacteroides 
fragilis, another bacterium that produces short-chain fatty acids. Farup et al. states that “lack of 
butyric acid has weight-inducing effects and metabolic consequences that are unfavourable for 
subjects with obesity” (2019). Tests also showed increased amounts of Ruminococcus gnavus, 
which multiple studies have associated as a prevalent gut microbe in Crohn's disease (Henke et 
al., 2019). There was also an increase in the Streptococcus species. 
One strength of this study was that it took into account the following variables: 
gender, age, height, weight, BMI, coffee (cups/day), smoking (daily, previously, and never), 
previous and present diseases, and use of metformin and other drugs (yes/no). A limitation of 
this study was that the specific types of NNSs were not discussed. Also, the tests measured fecal 
amounts of short-chain fatty acids which could be construed as a poor estimate of short-chain 
fatty acids in the colon. On the other hand, perhaps measuring fecal SCFA was sufficient 
because quantities in feces depend on colonic production. Therefore, fecal measurements 
indirectly reflect intestinal quantities and activity. 
The nursing implication of this study is that consumption of nonnutritive sweeteners 
should be discouraged, especially for individuals with prediabetes, type 2 diabetes, obesity or 
metabolic syndrome. NNS consumption for reducing caloric intake or weight loss counteracts 
the beneficial effects that butyric acid has on metabolism like reducing insulin resistance and 
improving dyslipidemia. Nonnutritive sweeteners should be avoided because they decrease 
beneficial gut microbiota populations and induce glucose intolerance.  
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Activities That Promote Good Gut Health 
The article Exercise and Associated Dietary Extremes Impact on Gut Microbial Diversity 
by Clarke et al (2014) explored the positive impact that exercise and diet can have on gut 
microbiota. It was difficult to find studies about exercise and changes on microbiota that 
involved human participants, and not mice. Maybe it was difficult because there are many 
confounding variables when measuring results from exercise. 
This study included 86 total subjects from Cork County in Ireland. Of the 63 subjects, 
forty (n=40) were male elite professional rugby players. The mean age was 29 (+ 4) years. The 
remaining 46 subjects were healthy male controls with a mean age of 29 (+6) years. The two 
groups of control were divided into a low BMI group < 25 (n=23) and a high BMI group >28 
(n=23). Participants were excluded if they had a BMI between 25 and 28, antibiotic treatment 
within the previous 2 months or were suffering from any acute or chronic cardiovascular, GI or 
immunological condition (Clarke et al., 2014).  All participants were interviewed by a 
nutritionist and completed a detailed food frequency questionnaire that required diet recall from 
the past 4 weeks. Fecal and blood samples were collected and DNA was extracted from fresh 
stool samples which were stored on ice prior to use. The 40 athletes had to participate in a 
rigorous training camp and the physical activity levels of both control groups were assessed. The 
participants in the control groups were lean but considered sedentary. After four weeks, the fecal 
samples were examined using 16s rRNA sequencing. This was a quantitative, comparative study. 
The results revealed that the athlete microbiota had a greater alpha diversity and a higher 
relative abundance of 40 different bacterial taxa compared to the microbiota of both sedentary 
controls (Clarke et al., 2014). Also, the alpha diversity of the two control groups did not differ 
significantly from each other. In other words, high or low BMI did not have an effect on 
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microbiota diversity. In terms of diet, the athlete group consumed “significantly higher quantities 
of calories, protein, fat, carbohydrates, sugar and saturated fat per day than either of the control 
groups and consumed significantly higher quantities of fibre, monounsaturated fat and 
polyunsaturated fat than the high BMI control group” (Clarke et al., 2014). In summary, the 
results of this study suggest that diet and exercise are contributors to diversity in the gut. 
The nursing implication for this study is that exercise, coupled with healthy eating habits, 
can improve the diversity of the gut. Patients are frequently told that caloric energy spent should 
equal caloric consumption in a dry, mathematical type equation. The interaction of food, exercise 
and gut microbiota, which is considered a type of metabolic organ, is much more complex than a 
simple equation of counting calories in versus calories out. Teaching patients about the changes 
that occur at the microscopic level due to exercise and diet could guide interventions that focus 
more on microbiome health and less on strict calorie counting. 
The article Gut Bacteria Selectively Promoted by Dietary Fibers Alleviate Type 2 
Diabetes by Zhao et al. (2018) aimed to show that certain short-chain fatty acid-producing 
bacterial strains are promoted by dietary fibers which results in better hemoglobin A1c levels. 
This quantitative, randomized clinical study included specifically designed diets equal in energy, 
and fecal analysis using shotgun metagenomics to show that fiber increased the diversity and 
abundance of SCFA producers which in turn led to improved hemoglobin A1c levels (Zhao et 
al., 2018). 
Patients with clinically diagnosed type 2 diabetes were randomized. The control group (U 
group; n = 16 patients) received the standard care according to 2013 Chinese Diabetes guidelines 
for T2DM, which includes patient education and diet recommendations (Zhao et al., 2018). The 
treatment group (W group; n = 27 patients) received a high-fiber diet composed of whole grains, 
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traditional Chinese medicinal foods, and prebiotics (also called the WTP diet) (Zhao et al., 2018) 
Both groups received an anti-diabetic prescription medication similar to metformin, called 
acarbose as the standardized medication. The daily energy and macronutrient intake were similar 
for both groups but the authors wanted the treatment group (W) to have a higher intake of dietary 
fibers to see if it would improve the HbA1c of the subjects. The subjects had their baseline 
hemoglobin A1c levels, fasting blood glucose levels, postprandial glucose levels, body weight 
and blood lipid profiles taken before the study (Pre; day 0) and after the treatment (Post; day 84). 
The clinical data showed that although both groups showed improved glycemic control, “the 
proportion of the participants who achieved adequate glycemic control (HbA1c < 7%) at the end 
of the intervention was also significantly higher in the W group (89% versus 50% in the U 
group)” (Zhao et al., 2018). The W group also showed a greater reduction in body weight and 
better blood lipid profiles than the U group. These findings indicate that increased availability of 
nondigestible, fermentable carbohydrates is “sufficient to induce clinically relevant metabolic 
improvements in patients with T2DM” (Zhao et al., 2018). 
To determine causality between the gut microbiota and fiber-induced improvement of 
host glycemic control, two fecal samples were collected from the same participant; one from pre-
intervention and one post-intervention. The gut microbiota from each of the fecal samples was 
then transplanted into germ-free mice (Zhao et al., 2018). Mice that received post-intervention 
microbiota from the W group had the lowest fasting and postprandial blood glucose levels 
among all mice which reflected the better metabolic outcomes in participants of the W group 
than in those of the U group (Zhao et al., 2018). The transferable effects of the treatments via 
microbial transplantation provided evidence that the gut microbiota can improve glucose 
regulation in patients with T2DM when gut microbiota is provided fiber to “eat.” 
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The nursing implication for these findings is that nurses should encourage patients with 
dysfunctional glucose regulation to eat fiber. Feeding fiber to gut microbiota helps them flourish. 
When certain microbes ferment fiber they produce short-chain fatty acids that act as important 
metabolites for their human host. For example, short-chain fatty acids play a role in glucose 
regulation and lipid metabolism, and possibly reduce the risk of developing GI disorders like 
Crohn’s, anti-inflammatory diseases, cancer, and cardiovascular disease (Tungland, 2018).  
Repopulating the gut with SCFA-producing bacteria may be the best way to treat various 
dysbiosis-related diseases, including diabetes, or at least an effective way to prevent the disease’s 
progression. 
Discussion 
In summary, the aim of this literature review was to explore the connection between the 
gut microbiome and altered glucose metabolism. This review included six articles in total. Two 
articles identified the existence of a relationship between the gut microbiome and glucose 
metabolism dysfunction. Two articles illustrated that the gut microbiome can be negatively 
impacted by antibiotic use and artificial sweetener consumption. The last two articles illustrated 
that exercise and fiber consumption can promote healthy and diverse gut microbiota.  
One strength of some of the studies was that they collected objective data and used 
advanced technology, such as 16s rRNA sequencing, for their analysis. A limitation was that a 
couple studies population samples were relatively small or from other parts of the world. Also, 
some of the findings may not be generalizable conclusions because of difficulty in controlling 
relevant confounding variables. Restricting patients to identical diets may be one way to control 
the confounding variables of diet assessment. Further studies on this topic could include bigger 
sample sizes and longitudinal studies. Nevertheless, the findings of this literature review are 
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definitely eye-opening and worthy of guiding practice in the prevention and treatment of glucose 
metabolism dysfunction. 
Proposal for Further Study 
It is clear that further studies are needed to explore how healthy gut microbiota promotion 
leads to better outcomes for people with prediabetes. In my literature review, I did not encounter 
quantitative research comparing a prediabetic group receiving conventional pharmacological 
treatment with a prediabetic group receiving educational intervention regarding practices that 
promote healthy gut flora. Traditional approaches to treat people with prediabetes are failing. 
According to Anthony Komaroff, MD, at Harvard Medical School, 25% of people with 
prediabetes will develop full-blown diabetes within 3-5 years and the percentage is significantly 
larger over the long term (2013). This prognosis could be due to a one-size-fits-all protocol 
treatment that focuses on symptoms of the disease instead of the cause. According to Medscape, 
people newly diagnosed with insulin deficiency or resistance are usually advised to reduce 
weight by 5-10%, exercise 30-60 minutes at least 5 times per week, eat or not eat certain foods, 
and take medication (2020). Many of the medications prescribed to patients with prediabetes are 
the same as those given to patients with type 2 diabetes. These medications treat the symptoms 
of dysbiosis such as elevated glucose levels, hyperlipidemia, and high blood pressure. These 
medications do not treat the cause of dysbiosis, so people are left with a lifelong list of 
prescriptions that carry with them side effects that often lead to nonadherence. Can patient 
education and further research on the relationship between gut microbiota health and chronic 
diseases like diabetes lead to better outcomes for patients with prediabetes? 
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Theoretical Framework 
The nursing theory of Fay Abdellah serves as the framework for this study. According to 
the National Women’s Hall of Fame website, Dr. Faye Abdellah was an educator, and the first 
nurse and woman to serve as Deputy Surgeon General (1981-1989) (2020).  She helped 
transform the practice of nursing from “a disease-centered to a patient-centered approach,” and 
raised the standards of nursing practice “by introducing scientific research into nursing and 
patient care” (National Women’s Hall of Fame website, n.d.). The National Library of Medicine 
states that Dr. Abdellah advocated for nursing education to be based on science and research, for 
nurses to teach self-care to patients, and for an interdisciplinary approach to nursing care (2020). 
Faye Abdellah’s Twenty-One Nursing Problems Theory embodies the theoretical 
framework for this study.  These twenty-one nursing problems are broken down into ten steps 
used to identify the patient’s problems, and eleven skills used to develop a nursing care plan. The 
framework focuses on individualizing patient care, problem-solving, and patient-centered 
therapeutic plans. Skills of communication and education of patients and families are just two of 
her 11 skills listed (Abdellah, 1968).  These are important aspects of this proposed study. For 
example, traditionally, the prediabetic patient is instructed to lose weight by avoiding sugar and 
excess calories. This explanation alone would result in patients reaching for foods that are low 
calorie or sugar-free, but that may also contain highly processed ingredients that wreak havoc on 
gut microbiota. The hypothesis of this study is that patient education will lead to a better 
understanding of the disease process which will ultimately guide patient behaviors and improve 
glucose metabolism. 
Another step Faye Abdellah used to identify the patient’s problem was “explore the 
patient and his or her family’s reactions to the therapeutic plan and involve them in the plan” 
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(Abdellah, 1968). The success of a treatment plan depends on patient adherence. If the patient is 
actively involved in the formulation of the treatment plan, the patient will take more ownership 
of the implementation. Although diabetes causes common signs and symptoms in patients, a one-
size-fits-all approach is not effective in treatment. The patient, and not the disease, will guide the 
details of a treatment plan in this study. Focusing on patient education and care plan 
individualization is paramount to this study and thus aligns well with Faye Abdellah’s nursing 
theory. 
Primary Research Aims 
• This proposed quantitative, experimental study aims to compare fasting blood glucose 
and A1c, and microbial composition between two groups of prediabetic patients, one 
control group receiving usual care and an intervention group receiving weekly 
educational meetings and guidance on how to re-establish a healthy and diverse gut 
microbiome 
• The hypothesis of this study is that the prediabetic group who participate in the 
educational program will have better markers of blood glucose control and an improved 
microbiota composition by the end of the study compared to the prediabetic group who 
only receive usual care 
Ethical Considerations 
The participants will be given a letter with the purpose of the study and what 
participation entails. Participants will be informed that they can drop out at any point in the study 
if they wish. Their participation is completely voluntary. The participants will not be 
compensated for their participation, but could hypothetically improve their health. The letter will 
state that there will not be any economic risk, psychological risk, nor physical risk as long as 
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moderate exercise is not contraindicated. The only physical discomfort will be from having 
blood samples collected three separate times. Participants’ privacy and confidentiality will be 
honored throughout the process. Data collected will be used for research purposes only and 
stored in a password-protected computer to maintain strict confidentiality. The proposed study 
will be approved by Kaiser Permanente San Rafael’s Internal Review Board. 
Research Method 
This proposed quantitative study will compare fasting blood glucose, A1C, and 
microbiota composition from two groups of prediabetic participants before the study begins, 
after the treatment, and 24 weeks after the beginning of the study. The population sample will 
include men and women from 25 to 65 years old who meet the criteria of prediabetic and who 
are patients at Kaiser San Rafael. The proposed sample size will consist of 100 prediabetic adults 
who will be randomly divided into two groups. The treatment group, Group A, will consist of 50 
patients who will participate in an intensive educational program of hour-long weekly meetings 
for 12 consecutive weeks. The weekly discussions will cover evidenced-based research and 
literature on ways to promote a healthy gut microbiome as a means to obtain normal blood 
glucose regulation. Activities that harm the gut and diminish microbe diversity, such as taking 
antibiotics and consuming artificial sugar sweeteners, will also be discussed. Discussions will 
explain exactly how certain activities, like eating fiber and exercising, promote a healthy 
microbiome. The control, Group B, will consist of fifty patients who will not receive treatment in 
the form of an educational program. The only possible intervention Group B will receive are the 
standard verbal recommendations provided by their physicians. All participants will provide a 
baseline fasting blood glucose, HbA1C, and a fecal sample before the start of the study, after 12 
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weeks when the study concludes, and again at 24 weeks from the start of the study to test for 
long term effects. 
Recruitment for this study will involve identifying Kaiser patients that meet inclusion 
criteria. Inclusion criteria include being prediabetic as defined as having a fasting blood glucose 
between 100 mg/dl and 126 mg/dl and a hemoglobin A1c from 5.7% to 6.4% (Dansinger, 2019).  
Exclusion criteria include antibiotic treatment within the past two months, current metformin or 
other antihyperglycemic therapy, or suffering from any severe cardiovascular, gastrointestinal or 
immunological condition. After identifying eligible patients, researchers will contact patients 
who will be given a brief description of the study, expected requirements for participation, and 
hypothesized outcomes. Patients will then be asked if they would like to volunteer. Patients will 
be informed that in the event they are randomly chosen for the control group, they will be able to 
attend an educational program at the end of the study if they chose. In this way, a service that is 
deemed beneficial is being offered to both groups but just not simultaneously. Participants will 
be reminded that even after providing informed consent, they can stop participating at any time. 
For this quantitative, experimental study, a t-test will determine if there is a significant 
difference between the two groups’ fasting blood glucose and HbA1c pre-treatment and post-
treatment. 16s rRNA gene sequencing will be used to measure the microbial diversity and 
composition of the provided fecal samples from the two groups at the three different points in 
time. Gas chromatography and flame ionization detection will specifically measure the quantity 
of short-chain fatty acids, such as butyrate, in the stool samples as this is the byproduct of certain 
beneficial gut microbes. These beneficial species assist in gut homeostasis by their 
immunomodulatory functions as well as by maintaining metabolism such as blood glucose 
regulation (Nepelska et al., 2012). 
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Conclusion 
After a thorough literature review of research, it is evident that there is a strong 
relationship between the health of the gut microbiome and human health. Gut dysbiosis and its 
role in the pathogenesis of disease needs to be further explored as it has been noted in patients 
with glucose metabolic dysfunction. More research is also needed on the beneficial role of the 
short-chain fatty acids produced by bacteria in the gut. Technological advances have made 
identification of gut microbial taxa possible, and the association between certain taxa and 
systemic inflammatory diseases is becoming evident. In the future, the presence of certain 
microbial populations or the absence of others might be used as biomarkers for diagnosing 
inflammatory diseases such as diabetes, ulcerative colitis, Crohn’s disease, multiple sclerosis, 
rheumatoid arthritis, psoriasis and even cardiovascular disease (Barnes et al., 2016). To date, the 
majority of data analysis of microbial communities’ role in disease has been collected from 
research on mice. The number of studies on human participants is growing at the same time as 
the prevalence of inflammatory diseases is growing, and scientists are desperately searching for 
their etiologies. The effectiveness of fecal microbiota transplantation in the treatment of 
Clostridium difficile infection has made manipulation of the gut microbiota even more attractive 
as a treatment option for diabetes and idiopathic conditions (Borody, 2011).  In the future, fecal 
samples may be collected as routinely as blood samples to diagnose and treat inflammatory 
conditions.  
This proposed research study with prediabetic patients will advance the nursing 
profession by exploring alternative methods to correct dysfunctional glucose metabolism. This 
proposed study uses Faye Abdellah’s theory of nursing care by focusing on treatment that is 
patient-centered instead of disease-centered. The twelve-week educational program will allow 
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patients to understand the “why” behind specific recommendations which will lead to better 
treatment adherence and in turn better glucose regulation.  Patients will understand that 
maintaining diverse and rich gut microbiota reduces inflammation and promotes healthy glucose 
metabolism. This study shifts the focus of nursing care from symptom management to patient 
education providing an opportunity for patients to take part in the prevention of their disease 
development. Patients will avoid a life sentence of pharmacological therapy, hospital visits, and 
potential complications such as amputations, end-stage kidney disease and dialysis treatment. In 
the future, more research is needed to explore the “neglected endocrine organ,” known as our gut 
microbiota (Clarke et al., 2014). Let’s listen to our gut. 
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• Compare gut 
microbiota of 134 
adults with 
prediabetes, 
overweight, 
dyslipidemia and 
low-grade 
inflammation and 
134 individuals with 
normal glucose 
regulation.  
• Determine whether 
specific gut 
microbiota profiles 
are associated with 
prediabetes and a 
range of clinical 
biomarkers of poor 
metabolic health. 
 
n=268  
134 Danish adults 
with prediabetes and 
134 Danish adults 
with normal blood 
glucose regulation. 
Participants were 
same sex and 
roughly same age.  
 
Quantitative, case-
control study 
• Analyzed the gut 
microbiome and 
differences in 
populations of 
certain bacteria of 
268 Danish adults 
via fecal samples. 
• Individuals with 
prediabetes have 
aberrant intestinal 
microbiota 
characterized by a 
decreased 
abundance of the 
genus Clostridium 
and the mucin-
degrading bacterium 
A. muciniphila.  
 
 
• Quantitative data 
from population 
sample having 
specific inclusion 
criteria allowing for 
better isolation of 
factors to be 
compared.  
 
• Dietary habits only 
reliably compared 
between individuals 
with prediabetes and 
normal glucose 
regulation in a 
subset of the cohort.  
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•Explore the 
relationship of gut 
microbiota with the 
development of type 
2 diabetes by 
analyzing metabolic 
parameters and 
microbiota diversity.  
N=121 
A total of 121 
subjects from China 
were broken up into 
3 groups based on 
their glucose 
intolerance status: 
normal glucose 
tolerance (NGT; 
n = 44), prediabetes 
(Pre-DM; n = 64), or 
newly diagnosed 
T2DM (n = 13). 
 
Quantitative, 
comparative 
observational study 
•Gut microbiota 
characterizations 
were determined 
with 16S rDNA 
sequencing. 
•Clinical 
characteristics were 
also measured 
to assess the 
correlation between 
metabolic 
parameters and 
microbiota diversity 
using Kruskal-
Wallis H tests.  
•Anthropometric 
and metabolic 
characteristics 
included body mass 
index, waist-hip 
ratio, fasting plasma 
glucose, plasma 
glucose 2 hrs after 
oral glucose 
challenge, 
•Findings provide 
evidence of 
structural 
modulation of gut 
microbiota in the 
pathogenesis of 
diabetes. 
•A significant 
association between 
metabolic 
parameters and gut 
microbiota (T2DM-
related gut 
dysbiosis) was 
found. 
•A total of 28 
operational 
taxonomic units 
were found to be 
related to T2DM. 
•Butyrate-producing 
bacteria had a higher 
abundance in the 
NGT group than in 
•Quantitative data 
allowed for 
objective analysis.  
•A large number of 
metabolic 
parameters were 
used.  
•A large number of 
bacteria ere 
analyzed. A total of 
2.2 million sequence 
reads were 
generated from the 
16S rDNA gene V3–
V5 amplicons, with 
an average of 9474 
(±3470 SD) reads 
per subject. 
•No subjects were 
taking antibiotics, 
hormones, or other 
drugs such as 
glucose- or lipid-
lowering agents so 
they could not 
•No dietary 
information was 
provided in the 
study. This may be a 
confounding factor 
because it has 
frequently been 
reported that the fat 
and fiber content of 
diets can affect gut 
microbiota 
composition. 
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triglyceride, fasting 
insulin 
concentration, 2-hr 
insulin 
concentration, 
insulin resistance 
index, and C-
reactive protein 
values. 
 
the pre-DM group. 
•Verrucomicrobiae  
may be a potential 
marker of T2DM-it 
had a significantly 
lower abundance in 
both the pre-DM and 
T2DM groups.  
 
 
significantly change 
the gut microbiota 
composition. 
 
Doan, T., Arzika, A. 
M., Ray, K. J., 
Cotter, S. Y., Kim, 
J., Maliki, R., … 
Lietman, T. M. 
(2017). Gut 
Microbial Diversity 
in Antibiotic-Naive 
Children After 
Systemic Antibiotic 
Exposure: A 
Randomized 
Controlled 
Trial. Clinical 
Infectious 
• Evaluate effects of 
azithromycin on the 
gut microbiome 
diversity. 
 
n=80  
Eighty antibiotic-
naïve children 1-60 
months from Niger. 
Quantitative, 
randomized case 
control study 
• 80 children 
received either oral 
azithromycin or 
placebo. Fecal 
samples were 
collected 
immediately before 
treatment and 5 days 
after treatment for 
16S rRNA gene 
sequencing. 
 
 
 
 
• Oral administration 
of azithromycin 
definitively 
decreases the 
diversity of the gut 
microbiome of 
children in an 
antibiotic-naive 
community. 
 
• Similar age of 
participants.  
• No statistically 
significant 
differences in age, 
sex, breastfeeding, 
or solid food intake 
between the 2 study 
groups. 
• Quantitative data 
more reliable and 
objective. 
 
 
• Population sample 
young children in 
rural community 
rural Niger so results 
may not be 
generalizable 
• Stool was sampled 
only after 5 days. 
Longer period may 
be necessary to 
provide insight into 
the resilience of the 
gut microbiome.  
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Farup, P. G., 
Lydersen, S., & 
Valeur, J. (2019). 
Are Nonnutritive 
Sweeteners 
Obesogenic? 
Associations 
between Diet, Faecal 
Microbiota, and 
Short-Chain Fatty 
Acids in Morbidly 
Obese 
Subjects. Journal of 
• Explore changes in 
fecal microbiota and 
short-chain fatty 
acids associated 
with the diet 
(nonnutritive 
sweeteners) and 
evaluate metabolic 
sequences. 
• Demonstrate for 
adults trying to lose 
weight, use of NNSs 
is suspect because 
n=89 
Study included 14 
men and 75 women 
with a mean age of 
44.6, BMI 41.8, and 
intake of NNS 7.5 
units/day. 
Quantitative, cross 
sectional study  
• Fecal microbiota 
was assessed with 
GA-map dysbiosis 
test and SCFA with 
gas chromatography 
and flame ionization 
detection.  
• Participants diet 
was assessed with a 
validated food 
questionnaire.  
 
• Nonnutritive 
sweeteners 
counteract the 
favorable effects of 
butyric acid which 
has anti-obesogenic 
effects, reduces 
insulin resistance 
and improves 
dyslipidemia.  
• Fecal butyric acid 
was positively 
associated with the 
• Adjustment for 
multiple testing was 
performed for the 
main findings.  
• Analyses showed a 
showed a clear trend 
for an association 
between NNSs and 
butyric acid. 
• Quantitative data 
more reliable and 
objective. 
 
• Study restricted to 
only participants 
with morbid obesity. 
• Measurement of 
SCFA in feces and 
not in proximal parts 
of colon, so more of 
an estimate of 
colonic SCFA. 
• Test could have 
examined more than 
the 39 bacterial 
groups included. 
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they counteract the 
favorable effects of 
butyric acid.  
intake of starch and 
negatively 
associated with 
intake of NNSs.  
• NNSs were 
associated with 
changes in four out 
of 30 bacterial 
groups.  
 Types of NNSs not 
included. 
 
Clarke, S. F., 
Murphy, E. F., 
O’Sullivan, O., 
Lucey, A. J., 
Humphreys, M., 
Hogan, A., … 
Cotter, P. D. (2014). 
Exercise and 
associated dietary 
extremes impact on 
gut microbial 
diversity. Gut, 63(12
), 1913–1920. doi: 
10.1136/gutjnl-
2013-306541 
 
• Explore the impact 
of exercise and diet 
on the gut 
microbiota.  
• Demonstrate that 
diet and exercise 
influence each 
component of the 
signaling network 
triad: the commensal 
microbiota, host 
immunity and 
metabolism. 
n=63 
• 40 young adult 
male athletes 
(professional rugby 
players) and 23 
young, healthy adult 
males (the control) 
with similar BMI 
and age. 
• Participants from 
Cork in Ireland. 
 
 
Quantitative,  
exploratory study 
• Compositional 
analysis of the 
microbiota was 
explored by 16S 
rRNA amplicon 
sampling.  
• Each participant 
completed a detailed 
food frequency 
questionnaire. 
• Athletes had a 
higher diversity of 
gut microorganisms, 
representing 22 
distinct phyla, which 
positively correlated 
with protein 
consumption and 
creatine kinase.  
 
• Two groups made 
up of healthy 
individuals with 
similar BMIs and of 
similar age.  
• Quantitative data 
more reliable and 
objective. 
 
Athlete group on 
rugby team already 
physically fit, so 
presence of 
unknown 
confounder cannot 
be excluded.  
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• To demonstrate 
that a select group of 
short chain fatty 
acid-producing 
strains is promoted 
by dietary fibers and 
that most other 
potential producers 
are either 
diminished or 
unchanged in 
patients with T2DM. 
 
Patients from China 
with clinically 
diagnosed type 2 
diabetes were 
divided into the 
control group (n = 
16) or the treatment 
group (n = 27).  
Quantitative, 
randomized clinical, 
open label, parallel 
group study 
• Patients with  
T2DM were 
randomized to 
receive either the 
usual care (patient 
education and 
dietary 
recommendations 
based on the 2013 
Chinese Diabetes 
Society guidelines 
for T2DM) as the 
control group (n = 
16) or a high-fiber 
diet composed of 
whole grains, 
traditional Chinese 
medicinal foods, and 
prebiotics (the WTP 
diet) as the treatment 
group (n = 27 
patients) in an open-
label, parallel-group 
study. 
• Increased 
availability of 
nondigestible but 
fermentable 
carbohydrates is 
sufficient to induce 
clinically relevant 
metabolic 
improvements in 
patients with T2DM. 
• When the fiber-
promoted SCFA 
producers were 
present in greater 
diversity and 
abundance, 
participants had 
better improvement 
in hemoglobin A1c 
levels, partly via 
increased glucagon-
like peptide-1 
production.  
• Quantitative data 
was gathered and 
analyzed using 
standard laboratory 
tests and the 
advanced 
technology of 16s 
rRNA gene 
sequencing. Many 
metabolic 
parameters were 
measured to reach 
findings. 
•Sample size was 
small.  
•Confounding 
factors cannot be 
excluded. 
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• After the 
specifically designed 
isoenergetic diets 
were administered, 
fecal samples were 
collected and 
analyzed using fecal 
shotgun 
metagenomics. 
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